×

Intercept CEO: NASH epidemic of liver disease

3:16 PM ET Fri, 14 Nov 2014

Intercept Pharmaceuticals CEO Mark Pruzanski, provides insight to his company's efforts to tackle NASH, or nonalcoholic steatohepatitis, saying over 10 percent of the U.S. population is thought to have NASH. Pruzanski also weighs in on being a public company.